• 1
    Anonymous. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med 1991; 90: 107.
  • 2
    Van Cleemput J, Daenen W, Nijs J, Geusens P, Dequeker J, Vanhaecke J. Timing and quantification of bone loss in cardiac transplant recipients. Transpl Int 1995; 8: 196.
  • 3
    Rico H, Revilla M, Hernandez ER, Villa LF, Del Buergo MA, Alonso AL. Age-and weight-related changes in total body bone mineral in men. Miner Electrolyte Metab 1991; 17: 321.
  • 4
    Grampp S, Genant HK, Mathur A, et al. Comparisons of noninvasive bone mineral measurements in assessing age-related loss, fracture discrimination, and diagnostic classification. J Bone Miner Res 1997; 12: 697.
  • 5
    Sambrook PN, Kelly PJ, Keogh AM, et al. Bone loss after heart transplantation: a prospective study. J Heart Lung Transplant 1994; 13: 116.
  • 6
    Shane E, Rivas M, McMahon DJ, et al. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metabol 1997; 82: 1497.
  • 7
    Thièbaud D, Krieg MA, Gillard-Berguer D, Jacquet AF, Goy JJ, Burckhardt P. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest 1996; 26: 549.
  • 8
    Välimäki MJ, Kinnunen K, Tähtelä R, et al. A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin. Ost Int 1999; 10: 128.
  • 9
    Kerschan-Schindl K, Strametz-Juranek J, Heinze G, et al. Pathogenesis of bone loss in heart transplant candidates and recipients. J Heart Lung Transplant 2003; 22: 843.
  • 10
    Zittermann A, Schleithoff S, Koerfer R. Markers of bone metabolism in congestive heart failure. Clin Chim Acta 2006; 366: 27.
  • 11
    Seibel MJ, Pols HPA. Clinical applications of biochemical markers of bone metabolism. Second edition. In: MarcusR, FeldmanD, KelseyJ, eds. Osteoporosis. New York: Academic Press, 2001; 1293.
  • 12
    Zuckermann A, Bohdjalian A, Deviatko E, et al. The University of Vienna experience in heart transplantation. In: CeckeM, TerasakiPI, eds. Clin Transpl. Los Angeles: UCLA Immunogenetics Center, 2002; 229.
  • 13
    Genant HK, Wu CY, Van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8: 1137.
  • 14
    Bartsch W. Interrelationships between sex hormone-binding globulin and testosterone, 5 alpha-dihydrotestosterone and oestradiol-17 beta in blood of normal men. Maturitas 1980; 2: 109.
  • 15
    Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981; 53: 58.
  • 16
    Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. Perspective: the diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137.
  • 17
    Brown H, Prescott R. Applied Mixed Models in Medicine. Chichester: John Wiley & Sons, 1999: 199.
  • 18
    Shane E, Rodino MA, McMahon DJ, et al. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J Heart Lung Transplant 1998; 17: 1089.
  • 19
    Muchmore JS, Cooper DK, Schlegel V, Pribil A, Zuhdi N. Prevention of loss of vertebral bone density in heart transplant patients. J Heart Lung Transplant 1992; 11: 959.
  • 20
    Lee AH, Mull RL, Keenan GF, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 1994; 96: 35.
  • 21
    Shane E, Rivas M, Kim TS, Staron RB, Bilezikian JP. Osteoporosis after cardiac transplantation. Am J Med 1993; 94: 257.
  • 22
    Shane E, Rivas M, Staron RB, et al. Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab 1996; 81: 1740.
  • 23
    Leidig-Bruckner G, Hosch S, Dodidou P, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001; 357: 342.
  • 24
    Rich GM, Mudge GH, Laffel GL, LeBoff MS. Cyclosporine A and prednisolone-associated osteoporosis in heart transplant recipients. J Heart Lung Transplant 1992; 11: 950.
  • 25
    Shane E, Addesso V, Namerow PB, et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 2004; 350: 767.
  • 26
    Reid IR. Glucocorticoid osteoporosis – mechanisms and management. Eur J Endocrinol 1997; 137: 209.
  • 27
    Nowacka-Cieciura E, Durlik M, Cieciura T, et al. Positive effect of steroid withdrawal on bone mineral density in renal allograft recipients. Transplant Proc 2001; 33: 1273.
  • 28
    Junge G, Neuhaus R, Schewior L, et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacolimus versus mycofenolate mofetil and tacolimus in liver transplant recipients with autoimmune hepatitis. Transplant Proc 2005; 37: 1695.
  • 29
    Lavee J, Bar-Zohar D, Har-Zahav Y, et al. Immunosuppression induction with rabbit antithymocyte globulin in heart transplantation patients: 6-year experience at the Sheba Medical Center. Transplant Proc 2000; 32: 737.
  • 30
    Norman DJ. Antilymphocyte antibodies in the treatment of allograft rejection: targets, mechanisms of action, monitoring, and efficacy. Sem Nephrol 1992; 12: 315.
  • 31
    Lum L, Wong BR, Josien R, et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dentritic cell survival. J Biol Chem 1999; 12: 1260.
  • 32
    Cenci S, Weitzmann MN, Roggia C, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α. J Con Invest 2000; 106: 1229.
  • 33
    Schlosberg M, Movsovitz C, Epstein S, Ismail F, Fallon MD, Thomas S. The effect of cyclosporine A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 1989; 124: 2179.
  • 34
    Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporine-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123: 2571.
  • 35
    Cvetkovic M, Mann GN, Romero DF, et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 1994; 57: 1231.
  • 36
    Mongeal A, Navvasa M, Guanabens N, et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 2001; 68: 83.
  • 37
    Stempfle HU, Werner C, Siebert U, et al. The role of tac-rolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 2002; 73: 547.
  • 38
    Dissanayake IR, Goodman GR, Bowman AR, et al. Mycofenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat. Transplantation 1998; 65: 275.
  • 39
    Bryer HP, Isserow JA, Armstrong EC, et al. Azathioprine alone is bone sparing and does not alter cyclosporine A-induced osteopenia in the rat. J Bone Miner Res 1995; 10: 132.
  • 40
    Torregrosa JV, Fuster D, Pedroso S, et al. Weekly risedronate in kidney transplant patients with osteopenia. Transpl Int 2007; 20: 708.
  • 41
    Khouzam RN, Dishmon DA, Farah V, Flax SD, Carbone LD, Weber KT. Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure. Am J Med Sci 2006; 331: 30.
  • 42
    Guo CY, Johnson A, Locke TJ, Eastell R. Mechanisms of bone loss after cardiac transplantation. Bone 1998; 22: 267.
  • 43
    Ramirez G, Narvarte J, Bittle PA, Ayers-Chastain C, Dean SE. Cyclosporine-induced alterations in the hypothalamic hypophyseal gonadal axis in transplant patients. Nephron 1991; 58: 27.
  • 44
    Stempfle HU, Werner C, Echtler S, et al. Prevention of osteoporosis after cardiac transplantation. Transplantation 1999; 68: 523.
  • 45
    Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, et al. Hormonal profile in patients with congestive heart failure. Int J Cardiol 2003; 87: 179.
  • 46
    Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725.